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An organization that effectively manages knowledge should be able to recognize and 
proactively apply new learnings to better anticipate risks. This is particularly important in the 
manufacture of medicinal products. Since the publication of ICH Q10 in 2010, Quality Risk 
Management (QRM) and Knowledge Management (KM) have been positioned as co-enablers 
to the Pharmaceutical Quality System.   The authors of this paper present a Knowledge 
Management process model to foster greater practical understanding of the practice of 
knowledge management.  This model when joined with the familiar ICH Q9 process model for 
QRM, should enable a company to better manage their knowledge and risk. In addition, a 
framework, the Risk-Knowledge Infinity Cycle is presented to better link these two disciplines 
at large and specifically as the dual enablers to ICH Q10.  It is the authors belief that treating 
QRM and KM in this way will have a variety of potential benefits for biopharmaceutical 
companies, including improved risk-based decision making, facilitating evidence-based risk 
reduction and increased process knowledge, leading to less uncertainty and subjectivity in 
QRM outputs.  This should ultimately result in more effective risk-based control strategies 
and more reliable manufacturing processes, which potentially lead to increased protection - 
and other benefits including product availability and value - for patients. This paper presents 
the Knowledge Management process model, and the Risk-Knowledge Infinity Cycle and an 





Since the introduction of ICH Q10 [1], the two enablers to the Pharmaceutical Quality System 
(PQS) being Quality Risk Management (QRM) and Knowledge Management (KM) have been 
treated as distinct and largely disconnected from each other in research and in practice.   
 
As part of a research effort by Lipa, O’Donnell and Greene, a key focus has been to unify QRM 
and KM in support of a more effective PQS and ultimately enhancing protection of the patient 
through improved quality risk management outcomes.  This research included a detailed 
literature review of how other industries link knowledge management and risk management, 
as well as an examination of the regulatory guidance on managing knowledge and risk 
relevant to the biopharmaceutical industry [2]. 
 
The purpose of this paper is to provide an introduction to a model to enhance the practical 
understanding of KM in the manner which QRM benefits from the process model depicted in 
ICH Q9 [3].  This model is presented as the Knowledge Management process model.  
Subsequently, a framework to better describe the link between KM and QRM is presented, 
the Risk-Knowledge Infinity Cycle.  Further detail on both this model and framework will be 
the subject of a subsequent publication in the Institute of Validation Technology [4] and 
Level3, a Technological University Dublin publication [5].  
 
2. Knowledge Management Process Model 
 
A Knowledge Management process model, which illustrates the role of KM in how an 
organization can manage its knowledge as an asset, is proposed by the authors and is 
presented here in (Figure 1).   
 
The model can be viewed as a KM analogue to the QRM process model presented in ICH Q9 
[3]. It encompasses the rather narrow definition of KM proposed by ICH Q10, being “a 
systematic approach to acquiring, analysing, storing, and disseminating information related 
to products, manufacturing processes and components,” and further enhances this definition 
by highlighting the need for knowledge to flow in to KM from various processes and to 
subsequently be applied to various processes in support of decisions or other objectives.  The 
model also features the need for KM practices to facilitate the management of both explicit 
and tacit knowledge, and channels for knowledge communication, exchange and sharing 







(CPV = continuing process verification  |  CAPA = Corrective Actions Preventative Actions) 
 
Figure 1 – Knowledge Management process model 
 
There are several important features to this model which have the opportunity to better 
define how KM can be practically applied.  These features will be discussed in subsequent 
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3. Risk-Knowledge Infinity Cycle 
 
Building on the detailed literature review and the two concepts established in a previously  
published paper by the authors in the Journal of Validation Technology [2], a simple 
framework was developed to link Risk and Knowledge. The first underlying concept is that 
knowledge in both an input and an output to risk management [2] .  The second concept is 
that knowledge has an inverse relationship with risk, such that the more knowledge one has, 
the less uncertainty and therefore, the less risk [2, 6]. This proposed simple framework, 
entitled the Risk-Knowledge Infinity Cycle  is presented in Figure 2, and provides a visualization 
of how risk and knowledge are connected.   
 
Figure 2 – The Risk-Knowledge Infinity Cycle 
 
In order to present an example of the application of this Risk-Knowledge Infinity Cycle, the 
authors applied the framework to ICH Q10, as illustrated in Figure 3, which depicts the how 




Figure 3 – The Risk-Knowledge Infinity Cycle applied to ICH Q10 
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There are several important features to this framework, its symbolism and practical 
application to ICH Q10, including an example to a sterile filling line, which will be discussed in 




The authors envision a unified approach to managing knowledge and risk as a foundation to 
the PQS as depicted in Figure 4. 
 
 
Figure 4 - A Re-framed and Unified PQS foundation 
On achieving this vision, QRM and KM together can better support each of the four PQS 
elements and have the potential to deliver additional benefit, including achieving true risk-
based control strategies, evidence-based risk reduction and more.  These benefits and 
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